Trial Profile
A multicenter, double-blind, randomized, placebo- and active-controlled dose-range finding study of MK0431 [sitagliptin] in patients with type 2 diabetes mellitus who have inadequate glycemic control
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme Corp.
- 27 Jul 2007 New trial record.